• The Journal of Asian Finance, Economics and Business
• /
• 제9권7호
• /
• pp.239-247
• /
• 2022

Maintaining and expanding brand equity is regarded as an essential component of brand development. Effective management of brand equity leads to more opportunities for brand extension and the ability to draw in more customers. Brand equity, in particular, has a positive impact on consumer purchase intention. The purpose of this study is to look into the relationships between brand equity and consumption intention from the perspective of Vietnamese customers of India's COVID-19 vaccine products. Primary data is aggregated from 475 Vietnamese citizens with different occupations and backgrounds 18 years of age or older. The findings of the study show that consumption intention is positively inspired by brand equity, including brand association and brand quality. If consumers perceive high brand equity, it will have a higher impact on promoting consumption intention to the brand. India's COVID-19 vaccine needs to invest more in building brand equity in the Vietnamese market if it wants to increase the consumption choices of Vietnamese people. To create a good brand association and brand quality for India's COVID-19 vaccine, it is necessary to focus on communicating the good properties of the Indian-made vaccine such as safe, high protective effect, high immunity and protection, and long duration of immunity of vaccines.

• Genomics & Informatics
• /
• 제20권2호
• /
• pp.22.1-22.9
• /
• 2022

The rise of newer coronavirus disease 2019 (COVID-19) variants has brought a challenge to ending the spread of COVID-19. The variants have a different fatality, morbidity, and transmission rates and affect vaccine efficacy differently. Therefore, the impact of each new variant on the spread of COVID-19 is of interest to governments and scientists. Here, we proposed mathematical SEIQRDVP and SEIQRDV3P models to predict the impact of the Omicron variant on the spread of the COVID-19 situation in South Korea. SEIQEDVP considers one vaccine level at a time while SEIQRDV3P considers three vaccination levels (only one dose received, full doses received, and full doses + booster shots received) simultaneously. The omicron variant's effect was contemplated as a weighted sum of the delta and omicron variants' transmission rate and tuned using a hyperparameter k. Our models' performances were compared with common models like SEIR, SEIQR, and SEIQRDVUP using the root mean square error (RMSE). SEIQRDV3P performed better than the SEIQRDVP model. Without consideration of the variant effect, we don't see a rapid rise in COVID-19 cases and high RMSE values. But, with consideration of the omicron variant, we predicted a continuous rapid rise in COVID-19 cases until maybe herd immunity is developed in the population. Also, the RMSE value for the SEIQRDV3P model decreased by 27.4%. Therefore, modeling the impact of any new risen variant is crucial in determining the trajectory of the spread of COVID-19 and determining policies to be implemented.

• 대한한방내과학회지
• /
• 제42권4호
• /
• pp.590-604
• /
• 2021

Objectives: The purpose of this study is to examine the safety of Korean medicine treatment in patients vaccinated with the AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/AZD1222). Methods: We investigated patients at Kyung Hee University Korean Medicine Hospital who were vaccinated with the AstraZeneca COVID-19 vaccine between June 1, 2021 and June 30, 2021. The safety of Korean medicine treatment was evaluated by examining adverse events that occurred within seven days of vaccination, including liver function and kidney function testing, assessment of the severity of adverse events, and examination of causality to vaccines and Korean medicine treatment. Results: Eleven patients vaccinated with the first dose of the AstraZeneca COVID-19 vaccine were included. A total of 19 adverse events were reported: 15 systemic adverse events, three local adverse events, and one alanine aminotransferase increase. The most commonly reported systemic adverse events were fatigue (4 cases, 36.4%), headache (4 cases, 36.4%), and myalgia (4 cases, 36.4%). All adverse events were rated below moderate (grade 2) in severity. Systemic and local adverse events were evaluated as definitely related to vaccination and unlikely to be related to Korean medicine treatment, while alanine aminotransferase increase was evaluated as unlikely to be related to either the vaccine or Korean medicine treatment. Aspartate transaminase, Blood urea nitrogen, and creatinine were measured within the reference range after vaccination. Conclusion: Our results suggest that the severity and frequency of adverse events in patients vaccinated with the AstraZeneca COVID-19 vaccine did not increase after Korean medicine treatment.

• 대한한방내과학회지
• /
• 제44권5호
• /
• pp.957-967
• /
• 2023

Background: According to Vaccine Adverse Events Reporting System data, generalized edema followed by the COVID-19 vaccine is uncommon, with only 333 reported cases, and of those, 224 (69%) are associated with the Pfizer-BioNTech vaccine. Case report: A 76-year-old male patient with heart failure with preserved ejection fraction presented with spontaneous generalized edema and otherwise normal cardiac exams following administration of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination that had lasted for approximately 60 days and was treated successfully using Korean medicine treatment. After the administration of Korean medicine treatment, the patient's symptoms in the bilateral limbs were dramatically controlled, without recurrence, for 2 months. As a result, generalized edema, which had been present for approximately 50 days, dramatically improved. Conclusion: This clinical case study suggests that a Korean medicine approach with Mokbangki-tang and Oryeong-san might be effective for the pleural effusion resolution of generalized edema after COVID-19 vaccination.

• 한국컴퓨터정보학회논문지
• /
• 제28권5호
• /
• pp.129-153
• /
• 2023

본 연구는 코로나19 팬데믹 상황이 심각하였을 때, 대중들의 관심도가 높은 코로나19 백신과 관련한 대량의 언론 보도 프레임을 분석하여, 위기커뮤니케이션의 핵심 요소로서 바람직한 언론의 역할과 방향성을 모색하기 위해 수행되었다. 본 연구의 기간은 코로나19 백신 개발이 가시화되기 시작한 2020년 11월부터 2021년 6월까지 8개월이며, 연구 대상은 대중 신뢰도 및 이용도 순위에 따라 조선일보, 중앙일보, 동아일보, 한겨레로 설정하였다. 결과의 정확성 및 효율성을 제고하기 위해 최신 빅데이터 연구 기법인 구조적 토픽 모델링(STM) 및 의미연결망 분석 기법을 활용하였다. 연구결과, 구성 단어들의 명확한 군집도 및 중심성 분석값을 기반으로 각 언론사 당 16개 프레임, 총 64개의 유의미한 프레임이 도출되었다. 또한 프레임의 구성 정도 및 내용에 대한 차이를 확인하기 위해 4개 언론사를 비교 분석하였으며, 모든 언론사마다 유의미한 차이가 없음을 확인하였다.

• Journal of Contemporary Eastern Asia
• /
• 제21권2호
• /
• pp.27-46
• /
• 2022

The purpose of this study is two-fold: first, to discuss the concept of health diplomacy and the Korean government's response to contain the COVID-19 pandemic; second, to assess and compare assumptions of variances about foreigners' perceptions of how Korea is leveraging digital technology in battling the coronavirus spread, and its vaccine campaign; through the lenses of Chinese, Filipino, and Pakistani foreign nationals who are currently living in Korea. A total of 219 foreigners responded to the survey. The collected data were analyzed as percentages, mean averages, t-test, and ANOVA for statistical analysis. Results show that Korea is utilizing its digital technology practices and vaccine campaign in battling the pandemic through efforts of health diplomacy. ANOVA indicated significant results and assumptions of variance across three ethnic groups showing the Pakistani population had higher mean scores than the Chinese and Filipino about Korea's health diplomacy during the pandemic. This study contributes to the literature on Korea's digital technology practices and vaccine campaigns amidst the COVID-19 pandemic by promoting its image through health diplomacy efforts. It projects the country's soft image on a global scale, to save the lives of locals and foreign nationals, by providing insights into health diplomacy in Korea.

• Journal of Digestive Cancer Research
• /
• 제10권2호
• /
• pp.107-111
• /
• 2022

In 2019, coronavirus disease (COVID-19), which originated in Wuhan, has spread worldwide. In most people, COVID-19 symptoms are not severe. However, the mortality rate and severity were high in risk groups such as in older people and patients with underlying diseases. As patients with cancer are one of the risk groups, the vaccination for COVID-19 is emphasized in these patients. However, COVID-19 vaccines are not tested enough in special groups such as in patients with cancer because these vaccines are developed at an unprecedented speed. This causes confusion about whether patients undergoing chemotherapy should be vaccinated or not. In this study, international guidelines and studies were reviewed. Most of the studies recommended vaccination. No evidences of any negative effects for the efficacy or safety were recorded in patients undergoing cytotoxic, targeted, and immune agents. However, in critical conditions such as cytopenia, vaccination must be decided according to the patient's condition. COVID-19 vaccines were also recommended for patients on surgery or radiation therapy. If possible, vaccine is given before surgery to avoid confusion between surgical complications and side effects of the vaccine. The radiation recall phenomenon after vaccination has been reported in some cases of radiation therapy. Clinicians should consider these situations before vaccinating each patient. We hope that clearer guidelines will be established by accumulating verified data.

• 항공우주의학회지
• /
• 제31권1호
• /
• pp.21-23
• /
• 2021

Purpose: Human papillomavirus (HPV) vaccination schedule is recommended by Strategic Advisory Group of Experts on Immunization of World Health Organization to achieve high efficacy and immunogenicity. However, the patients often cannot keep up their schedule for several reasons. Methods: Monthly numbers of visitors for HPV vaccination between 2019 and 2021 were analyzed to measure the impact of coronavirus disease-19 (COVID-19) outbreak which was the main cause of this delay. Results: In February 2020, the number of foreign patients vaccinated with HPV was dropped suddenly due to COVID-19. Prior to this impact, the average patients per month for HPV vaccination was 160 (95% confidence interval [CI]: 143-176). It was then 30 (95% CI: 20-40). However recent trends show a gradual recovery. Conclusion: If a woman is pregnant after starting the HPV vaccine series, the reminder doses should be delayed until she is no longer pregnant. If this series is interrupted for any length of time, it can be resumed without restarting the series. HPV vaccine series need to be administered with a minimum interval of 14 days before or after administration of COVID-19 vaccines.

• 대한족부족관절학회지
• /
• 제26권1호
• /
• pp.48-53
• /
• 2022

The current SARS-CoV-2 coronavirus disease 2019 (COVID-19) pandemic has been a particular challenge for diabetes patients. Since these patients are at a higher risk of COVID-19, they have been prioritized for vaccination. In this report, we describe the case of a patient scheduled for diabetic foot amputation who received the first dose of ChAdOx1 nCov-19 vaccine and subsequently developed severe purpura in his genitalia and both of his hands and feet, accompanied by acute renal failure. The operation had to be postponed as severe limb purpura appeared just before the operation. With adequate management for acute renal failure and topical steroid application for the severe purpura lesions, a successful outcome could be obtained after the delayed first ray amputation. We recommend that COVID-19 vaccination should be carefully administered in patients with a diabetic foot requiring amputation.

• Journal of Ginseng Research
• /
• 제45권4호
• /
• pp.535-537
• /
• 2021

In the 1918 influenza pandemic, more than 95% of mortalities were ascribed to bacterial pneumonia. After the primary influenza infection, the innate immune system is attenuated, and the susceptibility to bacteria is increased. Subsequent bacterial pneumonia exacerbates morbidity and increases the mortality rate. Similarly, COVID-19 infection attenuates innate immunity and results in pneumonia. In addition, the current pneumococcal conjugate vaccine may have limited defense against secondary pneumococcal infection after influenza infection. Therefore, until a fully protective vaccine is available, a method of increasing immunity may be helpful. Ginseng has been shown to increase the defense against influenza in clinical trials and animal experiments, as well as the defense against pneumococcal pneumonia in animal experiments. Based on these findings, ginseng is suspected to be helpful for providing immunity against COVID-19.